Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.48 |
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | TK1 | P04183 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8839789 | 0.89 | DUT (0.56) | DUTKIF11TK1ALOX15CYP2C9 | |
| SCHEMBL3487683 | 0.87 | KIF11 (0.50) | DUTKIF11CYP2C9TSHRSLC6A1 | |
| SCHEMBL16214813 | 0.84 | KIF11 (0.50) | DUTKIF11CYP2C9TSHRSLC6A1 | |
| SCHEMBL6522822 | 0.82 | TK1 (0.46) | DUTKIF11TK1ALOX15CYP2C9 | |
| SCHEMBL465454 | 0.82 | TK1 (0.46) | DUTKIF11TK1ALOX15CYP2C9 | |
| SCHEMBL4525211 | 0.81 | KIF11 (0.44) | DUTKIF11TK1ALOX15CYP2C19 | |
| SCHEMBL2178034 | 0.81 | KIF11 (0.44) | DUTKIF11TK1ALOX15CYP2C19 | |
| SCHEMBL6671844 | 0.79 | KIF11 (0.43) | DUTKIF11TK1ALOX15CYP2C9 | |
| SCHEMBL16281907 | 0.79 | KIF11 (0.50) | DUTKIF11TK1ALOX15CYP2C9 | |
| SCHEMBL2111572 | 0.79 | KIF11 (0.50) | DUTKIF11TK1ALOX15CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694672-B1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2012-06-20 | — | — | EP | disclosed |
| US-8143057-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2012-03-27 | — | — | US | disclosed |
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2010-02-11 | — | — | US | disclosed |
| US-7625930-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLOC OY (FI) | 2009-12-01 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
| EP-1694672-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2006-08-30 | — | — | EP | disclosed |
| US-20050181393-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2005-08-18 | — | — | US | disclosed |
| WO-2005058877-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | CLTA, CLTC, FOLH1 | DUT 83/4885KIF11 1668/4885TK1 77/4885 |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | DUT 83/4885KIF11 1668/4885TK1 77/4885 |
| US-20050181393-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | DUT 83/4885KIF11 1668/4885TK1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.